Find Tritriacontanoic Acid manufacturers, exporters & distributors on PharmaCompass

Tritriacontanoic Acid

Suanfarma, at the Core of a Better Life.

Contact Supplier

Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

Contact Supplier

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Contact Supplier

Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Contact Supplier

Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

Contact Supplier

xyz-pharma-m-2025-01-20

Contact Supplier

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

FINISHED DOSAGE FORMULATIONS

3 FDF Dossiers, 2 Europe, 1 Listed Dossiers

3 FDF Dossiers
2 Europe
1 Listed Dossiers

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow

media
1 DATA COMPILATION #PharmaFlow

GLOBAL SALES INFORMATION

2 Finished Drug Prices

globalSalesInformation
2 Finished Drug Prices

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

0

USDMF

0

CEP/COS

CEP/COS Certifications

0

JDMF

0

EU WC

0

KDMF

0

NDC API

0

VMF

0

Listed Suppliers

API REF. PRICE (USD/KG)

$

$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

3

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

2

Europe

0

Canada

0

Australia

0

South Africa

1

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

1

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

NA

Annual Reports (USD Million)

NA

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Click the button for full data set

Also known as: Psyllic acid, 38232-03-0, Ceromelissic acid, 8063-16-9, 5lsy5b2356, C33:0

Molecular Formula

C₃₃H₆₆O₂

Molecular Weight

494.9 g/mol

InChI Key

HQRWEDFDJHDPJC-UHFFFAOYSA-N

FDA UNII

5LSY5B2356

Tritriacontanoic Acid

Dried, ripe seeds of PLANTAGO PSYLLIUM; PLANTAGO INDICA; and PLANTAGO OVATA. Plantain seeds swell in water and are used as demulcents and bulk laxatives.

1 2D Structure

Tritriacontanoic Acid

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

tritriacontanoic acid

2.1.2 InChI

InChI=1S/C33H66O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33(34)35/h2-32H2,1H3,(H,34,35)

2.1.3 InChI Key

HQRWEDFDJHDPJC-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)O

2.2 Other Identifiers

2.2.1 UNII

5LSY5B2356

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Gum, Ispaghule

2. Isogel

3. Ispaghula

4. Ispaghule Gum

5. Metamucil

6. Plantaginis, Semen

7. Plantaglucide

8. Plantago Seed

9. Psyllium

10. Reguval

11. Seed, Plantago

12. Semen Plantaginis

2.3.2 Depositor-Supplied Synonyms

1. Psyllic Acid

2. 38232-03-0

3. Ceromelissic Acid

4. 8063-16-9

5. 5lsy5b2356

6. C33:0

7. Psyllium Seed Gum

8. Tritriacontanoicacid

9. Pysslostearic Acid

10. Unii-5lsy5b2356

11. Schembl7647614

12. Dtxsid90959174

13. Chebi:165446

14. Lmfa01010033

15. Zinc59065086

16. Fa 33:0

17. Yp58645

18. Fa(33:0)

19. Q2823315

2.4 Create Date

2005-08-09

3 Chemical and Physical Properties

Molecular Formula	C₃₃H₆₆O₂
Molecular Weight	494.9 g/mol
XLogP3	15.6
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	31
Exact Mass	494.50628134 g/mol
Monoisotopic Mass	494.50628134 g/mol
Topological Polar Surface Area	37.3 Å²
Heavy Atom Count	35
Formal Charge	0
Complexity	393
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Cathartics

Agents that are used to stimulate evacuation of the bowels. (See all compounds classified as Cathartics.)

FDF Dossiers

01

Rusan Pharma

India

CPhI WW Frankfurt

Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

Contact Supplier

Contact Supplier

India

Digital Content

Regulatory Info :

Registration Country : India

Tritriacontanoic Acid

Brand Name :

Dosage Form : Powder-Sachet

Dosage Strength : 3.5gm

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Product Web Link

Digital Content

02

PROCTER AND GAMBLE

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

03

Schwabe Pharma

Mexico

Pharma, Lab & Chemical Expo

Not Confirmed

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

01

Procter & Gamble International Operation...

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

02

Schwabe Pharma AG

Mexico

Pharma, Lab & Chemical Expo

Not Confirmed

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

01

Rusan Pharma

India

CPhI WW Frankfurt

Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

Contact Supplier

Contact Supplier

India

Digital Content

Regulatory Info :

Registration Country : India

Tritriacontanoic Acid

Brand Name :

Dosage Form : Powder-Sachet

Dosage Strength : 3.5gm

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Product Web Link

Digital Content

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

Top Biotech and Pharma Deals in April 2018

Top Biotech and Pharma Deals in April 2018

Insofar as pharma M&As are concerned, 2018 is turning out to be a milestone year with more than US$ 170 billion invested in the first quarter alone. While March saw a steep climb in deal values with the Cigna-Express Scripts US$ 67 billion acquisition, April remained significant for Novartis’ renewed interests in gene therapy — the Swiss pharma giant acquired AveXis, a clinical-stage gene therapy company, for US$ 8.7 billion. Novartis retains focus on gene therapy with US$ 8.7 billion AveXis buyout In a bid to secure its leadership position in gene therapy, Novartis struck a deal to acquire Illinois-based AveXis, a clinical-stage gene therapy company working to develop treatments of rare and life-threatening neurological genetic diseases. AveXis’ lead pipeline candidate is a neurology-targeted treatment based on virus-mediated gene therapy — AVXS-101. It has the potential to be the first one-time gene replacement therapy for spinal muscular atrophy (SMA), a disease which results in early death or lifelong disability with considerable healthcare costs. “What was remarkable and what we consider transformative – and frankly all the experts in the SMA field also feel the same – is that we had 100 percent survival of the children at 13.6 months of age, and 100 percent survival of the children at 20 months of age,” Sukumar Nagendran, the chief medical officer of AveXis said in an interview with SMA News Today. Click here to view the major deals in April 2018 (FREE Excel version available) In addition, AVXS-101 has attained the Breakthrough Therapy Designation in the US and the Sakigake Designation in Japan. Moreover, this therapy, which is currently in Clinical Phase 3 development, also has access into the PRIority MEdicines (PRIME) scheme in the EU.Novartis CEO Vas Narasimhan said recently the patient population for SMA was 23,500 people in established markets. A filing with the US Food and Drug Administration (FDA) for AVXS-101 is expected in the second half of 2018 and approval and launch in the US is expected in 2019. Click here to view the major deals in April 2018 (FREE Excel version available) P&G acquires Merck KGaA’s consumer healthcare business Proctor & Gamble, one of the world’s largest personal care goods manufacturer, announced in mid-April that it has agreed to buy Merck KGaA’s consumer health unit for US$ 4 billion (€3.4 billion). This was just weeks after GlaxoSmithKline announced its buyout of Novartis’ consumer healthcare joint venture for US$ 13 billion. Priced at US$ 4.2 billion, the deal enables P&G to expand its successful consumer healthcare business by adding a fast-growing portfolio of differentiated, physician-supported brands across a broad geographic footprint. P&G now has better access to the Asian and Latin American markets, and an enhanced product portfolio that includes vitamin brands like Femibion, Neurobion and Seven Seas. It also provides P&G with leadership in consumer healthcare, complementing its existing portfolio that includes brands like Vicks, Metamucil, Pepto-Bismol, Crest and Oral-B. According to Reuters, the purchase price for Merck’s business suggests the German consumer healthcare conglomerate climbed down from price demands of as much as US$ 4.71 billion (€4 billion), which may have deterred initial suitors such as Nestle. Click here to view the major deals in April 2018 (FREE Excel version available) Ionis is flush with cash as it bags deals with Biogen and AstraZeneca Carlsbad, California-based drug maker, Ionis Pharmaceuticals, which successfully brought Spinraza (nusinersen) to clinic, earned US$ 1 billion in cash from Biogen as the two companies expanded their research collaboration on neurological diseases. Biogen announced in April this year that the transaction builds upon the collaboration that produced Spinraza as well as two antisense drug candidates currently in the clinic, with the potential to advance up to seven more drug candidates to the clinic within the next two years. Biogen’s announcement came less than two weeks after AstraZeneca paid Ionis a US$ 30 million license fee for its potential treatment for nonalcoholic steatohepatitis (NASH) where the inhibition target is undisclosed. Click here to view the major deals in April 2018 (FREE Excel version available) Ionis stands to receive up to US$ 300 million in additional development and regulatory milestone payments, as well as tiered royalties from sales of the drug.Speaking about the development, Brett P. Monia, CEO and senior vice president of Antisense Drug Discovery at Ionis Pharmaceuticals said: “AstraZeneca has played a strategic role in advancing this program forward by providing both preclinical and development expertise in NASH that has contributed to the rapid advance of this drug into development. We look forward to AstraZeneca moving this program swiftly into clinical testing and ultimately to the market.” Click here to view the major deals in April 2018 (FREE Excel version available) Rise in immuno-oncology deals Shire announced it was selling its oncology business to French company Servier for US$ 2.4 billion, whilst Takeda said it was considering an acquisition bid for Shire. Servier has obtained the rights to Shire’s presently marketed chemotherapy agent, Oncaspar, and pancreatic cancer treatment, Onivyde. Additionally, Shire’s pipeline of immuno-oncology assets (including Calaspargase Pegol under priority review) are all part of the offerings that were made during the divestment to Servier. For Servier, the acquisition of Shire’s oncology franchise enables it to establish a stronger “commercial presence in the US as well as the ex-US territories where Servier is already present,” Olivier Laureau, President of the Servier Group, said. Two dedicated cancer immunotherapy companies — Allogene Therapeutics and Cellectis — together announced a joint asset contribution agreement involving select allogeneic CAR-T programs from Pfizer’s oncology portfolio for a massive US$ 2.8 billion. This deal also landed Allogene US$ 300 million in funding and Pfizer a 25 percent stake in the company. Click here to view the major deals in April 2018 (FREE Excel version available) The immune-oncology collaboration provides Allogene exclusive rights to develop 16 preclinical assets including UCART19 — a CAR T-cell product jointly developed by Servier and Pfizer that Pfizer had earlier licensed from Cellectis and Servier. Cellectis’ CAR-T platform provides an allogeneic approach of using engineered T-cells from healthy donors, which makes T-cell therapy more accessible to cancer patients. This is distinct from autologous approaches that require the patient’s own T-cells for targeting tumor cells. Early last month, Boehringer Ingelheim and OSE Immunotherapeutics entered into an immuno-oncology collaboration to develop OSE-172 — a novel antibody targeting myeloid lineage cells. Click here to view the major deals in April 2018 (FREE Excel version available) While this highlights Boehringer Ingelheim’s strategy to strengthen its core pillar of cancer immunology, Paris-based OSE stands to receive approximately US$ 1.2 billion (€1.1 billion) upon reaching pre-specified development, commercialization and sales milestones, plus royalties on worldwide net sales. Our view Deals by major pharmaceutical companies during the month of April continued to be driven by their focus on gene therapy and immuno-oncology. While companies like Novartis, Biogen, AstraZeneca and Boehringer-Ingelheim are betting big on drugs that are still in development, others like Proctor & Gamble, Servier and Takeda have chosen to acquire proven assets that will immediately contribute to their sales. All eyes are set on Pfizer, which is exploring a sale of its consumer healthcare business. However, the pharma major has seen potential suitors drop out and during an earnings call a few weeks ago, its chairman Ian Read ruled out a transformative deal. “I don’t see that we need a transformative deal or see one at an appropriate value,” Read had said. Even if the Pfizer deal does not prove to be transformative, the M&A deals in the first few months of 2018 surely indicate that the world of pharmaceuticals is transforming at a fast pace. Click here to view the major deals in April 2018 (FREE Excel version available)

Impressions: 3377

Global Sales Information

Do you need Business Intel? Ask us

Finished Drug Prices

01

Brand Name : Laxiplant Soft

Mexico

Pharma, Lab & Chemical Expo

Not Confirmed

02

Brand Name : Metamucil

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Tritriacontanoic Acid Manufacturers

A Tritriacontanoic Acid manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tritriacontanoic Acid, including repackagers and relabelers. The FDA regulates Tritriacontanoic Acid manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tritriacontanoic Acid API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Tritriacontanoic Acid Suppliers

A Tritriacontanoic Acid supplier is an individual or a company that provides Tritriacontanoic Acid active pharmaceutical ingredient (API) or Tritriacontanoic Acid finished formulations upon request. The Tritriacontanoic Acid suppliers may include Tritriacontanoic Acid API manufacturers, exporters, distributors and traders.

Tritriacontanoic Acid GMP

Tritriacontanoic Acid Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Tritriacontanoic Acid GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tritriacontanoic Acid GMP manufacturer or Tritriacontanoic Acid GMP API supplier for your needs.

Tritriacontanoic Acid CoA

A Tritriacontanoic Acid CoA (Certificate of Analysis) is a formal document that attests to Tritriacontanoic Acid's compliance with Tritriacontanoic Acid specifications and serves as a tool for batch-level quality control.

Tritriacontanoic Acid CoA mostly includes findings from lab analyses of a specific batch. For each Tritriacontanoic Acid CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Tritriacontanoic Acid may be tested according to a variety of international standards, such as European Pharmacopoeia (Tritriacontanoic Acid EP), Tritriacontanoic Acid JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tritriacontanoic Acid USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.

Market Place

Home

Menu

Post Enquiry

Market Place

Search